Harmony Biosciences (HRMY)
(Delayed Data from NSDQ)
$33.55 USD
+0.72 (2.19%)
Updated Aug 7, 2024 04:00 PM ET
After-Market: $33.78 +0.23 (0.69%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth F Momentum B VGM
Balance Sheet
Fiscal Year End for Harmony Biosciences Holdings, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 353 | 323 | 234 | 229 | 24 |
Receivables | 74 | 55 | 35 | 22 | 4 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 5 | 4 | 4 | 4 | 1 |
Other Current Assets | 18 | 18 | 11 | 8 | 2 |
Total Current Assets | 451 | 400 | 284 | 263 | 32 |
Net Property & Equipment | 0 | 1 | 1 | 1 | 1 |
Investments & Advances | 72 | 23 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 144 | 86 | 0 | 0 | 0 |
Intangibles | 137 | 161 | 144 | 162 | 72 |
Deposits & Other Assets | 7 | 4 | 4 | 1 | 2 |
Total Assets | 811 | 674 | 433 | 427 | 107 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 18 | 4 | 1 | 3 | 6 |
Current Portion Long-Term Debt | 15 | 2 | 2 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 123 | 71 | 49 | 132 | 13 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 8 | 2 | 1 | 0 | 0 |
Total Current Liabilities | 164 | 79 | 54 | 135 | 20 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 179 | 190 | 190 | 194 | 98 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 3 | 3 | 1 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 344 | 271 | 247 | 330 | 118 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 411 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 610 | 675 | 640 | 585 | 0 |
Retained Earnings | -143 | -272 | -454 | -488 | -423 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 467 | 403 | 187 | 97 | -12 |
Total Liabilities & Shareholder's Equity | 811 | 674 | 433 | 427 | 107 |
Total Common Equity | 467 | 403 | 187 | 97 | -423 |
Shares Outstanding | 58.57 | 59.32 | 58.40 | 56.80 | NA |
Book Value Per Share | 7.97 | 6.79 | 3.19 | 1.71 | 0.00 |
Fiscal Year End for Harmony Biosciences Holdings, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 347 | 372 | 353 | 371 | 371 |
Receivables | 83 | 80 | 74 | 67 | 64 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | 6 | 6 | 5 | 5 | 5 |
Other Current Assets | 23 | 22 | 18 | 20 | 16 |
Total Current Assets | 458 | 480 | 451 | 463 | 456 |
Net Property & Equipment | 1 | 0 | 0 | 0 | 1 |
Investments & Advances | 87 | 81 | 72 | 68 | 59 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | 180 | 148 | 144 | 100 | 94 |
Intangibles | 125 | 131 | 137 | 143 | 149 |
Deposits & Other Assets | 7 | 7 | 7 | 3 | 3 |
Total Assets | 858 | 847 | 811 | 778 | 760 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | 23 | 15 | 18 | 7 | 7 |
Current Portion Long-Term Debt | 15 | 15 | 15 | 15 | 11 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | 101 | 99 | 123 | 83 | 72 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | 8 | 25 | 8 | 8 | 4 |
Total Current Liabilities | 147 | 154 | 164 | 112 | 93 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | 171 | 175 | 179 | 182 | 180 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 2 | 2 | 1 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | 320 | 332 | 344 | 296 | 275 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 632 | 621 | 610 | 652 | 694 |
Retained Earnings | -93 | -105 | -143 | -170 | -208 |
Other Equity | 0 | 0 | 0 | -1 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 539 | 515 | 467 | 481 | 485 |
Total Liabilities & Shareholder's Equity | 858 | 847 | 811 | 778 | 760 |
Total Common Equity | 100,538 | 515 | 467 | 481 | 485 |
Shares Outstanding | 56.79 | 56.79 | 58.50 | 58.50 | 60.00 |
Book Value Per Share | 1,770.34 | 9.08 | 7.98 | 8.23 | 8.09 |